Neurocrine Biosciences, Inc. (NBIX) financial statements (2023 and earlier)

Company profile

Business Address 12780 EL CAMINO REAL
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments711801671651516307379
Cash and cash equivalents3411871121422558374
Short-term investments371614558509261224305
Receivables1861571275631  
Inventory, net of allowances, customer advances and progress billings31281711   
Inventory31281711   
Other current assets46301720835
Total current assets:9731,016831738555310384
Noncurrent Assets
Operating lease, right-of-use asset978374
Property, plant and equipment594542341163
Long-term investments and receivables5612273002162474382
Long-term investments5612273002162474382
Restricted cash and investments3335555
Deferred income tax assets315319 
Other noncurrent assets43     
Other undisclosed noncurrent assets613856    
Total noncurrent assets:1,1007194752552635591
TOTAL ASSETS:2,0731,7351,306993818365475
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:22616914186542622
Accounts payable   14653
Accrued liabilities   38182119
Employee-related liabilities5138392725  
Other undisclosed accounts payable and accrued liabilities17513110275  
Debt  409    
Deferred revenue and credits 00
Other liabilities20181520  
Other undisclosed current liabilities    144
Total current liabilities:24618756588543026
Noncurrent Liabilities
Long-term debt and lease obligation440412496388370  
Long-term debt, excluding current maturities335318409388370  
Operating lease, liability1059487
Liabilities, other than long-term debt12101718131212
Deferred revenue and credits131212
Deferred rent credit   18
Other liabilities121017  00
Other undisclosed noncurrent liabilities  (409)188812
Total noncurrent liabilities:4534221044243912025
Total liabilities:6996096695124455050
Stockholders' equity
Stockholders' equity attributable to parent1,3741,126637481372315424
Common stock0000000
Additional paid in capital2,0111,8501,7681,6601,5731,3711,341
Accumulated other comprehensive income (loss)(2)21(2)(2)(0)(1)
Accumulated deficit(636)(725)(1,133)(1,178)(1,199)(1,056)(915)
Total stockholders' equity:1,3741,126637481372315424
TOTAL LIABILITIES AND EQUITY:2,0731,7351,306993818365475

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1,1341,0467884511621520
Revenue, net1621520
Financial services revenue 33
Cost of revenue
(Cost of Goods and Services Sold)
   (5)(1)  
Gross profit:1,1341,0467884461601520
Operating expenses(1,031)(883)(716)(414)(293)(162)(114)
Other undisclosed operating income   51  
Operating income (loss):1031637237(131)(147)(94)
Nonoperating income (expense)(1)(56)(26)(15)(11)65
Investment income, nonoperating   1632
Interest and debt expense(26)(18)(32)(31)(20)  
Income (loss) from continuing operations before equity method investments, income taxes:768815(9)(162)(141)(89)
Other undisclosed income from continuing operations before income taxes26183231   
Income (loss) from continuing operations before income taxes:1011074722(162)(141)(89)
Income tax expense (benefit)(12)301(10)(1)   
Net income (loss):904073721(162)(141)(89)
Other undisclosed net income attributable to parent    20  
Net income (loss) available to common stockholders, diluted:904073721(143)(141)(89)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):904073721(162)(141)(89)
Comprehensive income (loss):904073721(162)(141)(89)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(4)03(0)181(1)
Comprehensive income (loss), net of tax, attributable to parent:864084021(144)(140)(90)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: